Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price dropped 19.4% during trading on Wednesday . The stock traded as low as C$0.14 and last traded at C$0.15. Approximately 215,053 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 513,395 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The stock has a market capitalization of C$22.59 million, a price-to-earnings ratio of -4.52 and a beta of 0.20. The company’s fifty day simple moving average is C$0.19 and its 200 day simple moving average is C$0.12. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- How is Compound Interest Calculated?
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- What is the Australian Securities Exchange (ASX)
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- 3 Warren Buffett Stocks to Buy Now
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
